Today: 11 April 2026
Subscribe
Browse Category

NASDAQ:SSB 9 February 2026

QQQ tug-of-war: SEC filings show fresh buying and a bank cut as Nasdaq tests faster Nasdaq-100 entry

QQQ tug-of-war: SEC filings show fresh buying and a bank cut as Nasdaq tests faster Nasdaq-100 entry

Paradigm Capital Management more than doubled its Invesco QQQ stake in Q3, raising holdings by 121% to 2,998 shares worth $1.8 million, filings show. Penserra increased its QQQ position by 26%, while SouthState Bank cut its stake by 45%. Nasdaq is seeking feedback on a rule to speed up adding large new listings to the Nasdaq-100.
9 February 2026
·······

Stock Market Today

  • Replimune Shares Slump Ahead of FDA Review Amid Negative Technical Signals
    April 11, 2026, 1:01 PM EDT. Replimune Group's stock fell Thursday ahead of an FDA decision due Friday on its RP1 treatment for advanced melanoma, previously rejected in June 2025 due to insufficient evidence from the IGNYTE trial. Internal FDA upheaval reportedly influenced the scrutiny. Shares trade at $5.79, down 20.7% below the 20-day moving average and 30.2% under the 100-day average, signaling weak short-term momentum. The Relative Strength Index (RSI) stands at 35.33, bordering bearish, while the Moving Average Convergence Divergence (MACD) also indicates selling pressure. Despite these challenges, Replimune holds $269.1 million in cash and equivalents, securing runway into early 2027. Over 12 months, the stock declined nearly 20%, reflecting a tough market for the biotech firm.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 1:14 PM EDT Replimune Shares Slump Ahead of FDA Review Amid Negative Technical Signals April 11, 2026, 1:01 PM EDT. Replimune Group's stock fell Thursday ahead of an FDA decision due Friday on its RP1 treatment for advanced melanoma, previously rejected in June 2025 due to insufficient evidence from the IGNYTE trial. Internal FDA upheaval reportedly influenced the scrutiny. Shares trade at $5.79, down 20.7% below the 20-day moving average and 30.2% under the 100-day average, signaling weak short-term momentum. The Relative Strength Index (RSI) stands at 35.33,
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop